PCI Biotech Holding ASA (PCIB) NOK3
0.1 NOK
(7.04%)
- Add to watchlist
- This stock can be held in a
0.1 NOK
(7.04%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.1 NOK
(7.04%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotech’s product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Contact details
Important dates
General stock information
- Short code:
- PCIB
- ISIN:
- NO0010405640
- Market cap:
- 53.00 million NOK
- Shares in issue:
- 37.33 million
- Sector:
- Biotechnology
- Exchange:
- Oslo Stock Exchange
- Country:
- Norway
- Currency:
- Norwegian Krone
- Indices:
- Oslo All Share Index
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.